Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print When physical and mental health problems co-occur and money gets tight, which prescriptions go unfilled?

When physical and mental health problems co-occur and money gets tight, which prescriptions go unfilled?

April 08, 2009

A new study points to a troubling connection between out-of-pocket expenses for people contending with both physical illnesses and depression, affecting access to antidepressant treatment.

Dr. Carolyn Dewa, head of the Work and Well-being Research and Evaluation Program at the Centre of Addiction and Mental Health (CAMH), and her team explored whether the amount of money spent on medication before a disability episode impacts medication use among workers on depression-related disability. This study built on previous research that revealed workers on depression-related short-term disability improved with antidepressant treatment.




"The results raised concerns about the treatment choices people are making," Dr. Dewa said. "As an example, if a worker's prior out-of-pocket expenses for medication associated with heart disease were $500, the probability of filling an antidepressant prescription was only 40 percent."

The CAMH team analyzed administrative disability data for three large firms with approximately 63,000 employees nationwide. The analysis, published in Healthcare Policy revealed that workers on depression-related short-term disability are more likely to fill a prescription for antidepressant medication if they have previously purchased antidepressants. This suggests that the medication is viewed as necessary, which may point to increased adherence to antidepressants, an issue that is frequently of concern in depression treatment.

At the same time, a worker on depression-related short-term disability is less likely to fill a prescription for antidepressant medication if the worker already is paying high out-of-pocket costs for medications to treat physical disorders such as heart disease or asthma (about 50 percent of employees studied had a co-morbid chronic physical disorder).

This phenomenon may be a barrier to accessing antidepressant treatment, which could delay taking necessary medication, impacting not only a person's recovery, but also a company's bottom line. Approximately one third of work-related productivity losses can be attributed to an employee being either unproductive or unable to function at full capacity because of depression. While recommended use of anti-depressants is associated with increased productivity and decreased disability, depression treatment is often complicated by physical disorders (e.g. heart disease, ulcers, hypertension, and asthma) that also require prescription drug treatment.

According to Dr. Dewa, a delay in use could cost an average of $2,924 extra (based on the average hourly wage of $21.66) per worker on depression-related short-term disability.

As Dr. Dewa explains, these findings highlight the dilemma faced by many employers - the desire to control rising costs of prescription drug benefits must be balanced with the fact that it's important not to create barriers to treatment. More research is needed to evaluate if drug benefits should be changed for workers on depression-related disability leave, especially those with a chronic physical condition.

Centre for Addiction and Mental Health



Related Antidepressant Treatment Current Events and Antidepressant Treatment News Articles Antidepressant Treatment Current Events and Antidepressant Treatment News RSS Antidepressant Treatment Current Events and Antidepressant Treatment News RSS
Popular antidepressant associated with a dramatic increase in suicidal thoughts amongst men
Nortriptyline has been found to cause a ten-fold increase in suicidal thoughts in men when compared to its competitor escitalopram. These findings are published in the open access journal BMC Medicine.

UCLA researchers develop biomarker for rapid relief of major depression
It is a long, slow slog to treat major depression. Many antidepressant medications are available, but no single biomarker or diagnostic test exists to predict which one is right for an individual.

Ketamine reduces suicidality in depressed patients
Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide.

New mouse model of depression/anxiety enhances understanding of antidepressant drugs
A recent study finds that the antidepressant effects of drugs like Prozac involve both neurogenesis-dependent and -independent mechanisms, a finding that may lead to development of better treatments for depression and anxiety.

How men and women cope differently with stress traced by Hebrew University researchers
Can people's differing reactions to situations of stress be attributed at least in part to genetic differences and do those differences affect men and women in different ways - with the edge seemingly favoring the women? Research conducted at the Hebrew University of Jerusalem would seem to indicate that the answer to both questions is yes.

Antidepressants in suicide prevention
Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement.

Use of sildenafil associated with improvement in antidepressant-related sexual dysfunction in women
Women with sexual dysfunction caused by the use of antidepressants experienced a reduction in adverse sexual effects with use of sildenafil, commonly known as the erectile dysfunction medication Viagra.

Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.

New study replicates association between genetic variation and antidepressant treatment response
Pharmacogenetics, the study of genetic variation that influences an individual's response to drugs, is an important and growing focus in all of medical research, including psychiatry.

NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression
New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression.
More Antidepressant Treatment Current Events and Antidepressant Treatment News Articles
  Antidepressant Treatment-The Essentials
by John H. & Thomas H. Greist (Author)



Curing Depression Anxiety & Panic Disorder

Curing Depression Anxiety & Panic Disorder
Directed By: Stefan Sargent
Also With: Burton Goldberg (Producer)



Diagnosing Depression (Home Use)

Diagnosing Depression (Home Use)

Depression: Treatments that Work It won't show up on a blood test or x-ray, but it is a leading cause of disability during the prime of life. It is depression and according to experts, depression actually affects more people in the U.S. than coronary artery disease, cancer or AIDS put together. However, the good news is treatments today are far more successful and wide ranging. This program highlights the latest breakthroughs in treatment and diagnostic tools spotlighting several people who have suffered with depression their entire lives, but are finding relief through a combination of treatment strategies and lifestyle changes. This program is part of the award winning public television series Healthy Body, Healthy Mind.

This product is manufactured on demand using DVD-R recordable...

Saffron Dietary Supplements, 60-Tablets The Worlds Most Exotic Spice is the Most Beneficial to Health, Made in the U.S.A.

Saffron Dietary Supplements, 60-Tablets The Worlds Most Exotic Spice is the Most Beneficial to Health, Made in the U.S.A.
by Epicure Garden

Epicure Garden is pioneering in bringing the goodness and benefits of saffron in Tablet form as Dietary Supplement into the world market. Recommendation: 1 tablet 2-3 times daily. It is All Natural, with No Artificial Colorings, No Additives or Sugar and made in the U.S.A. The world most exotic spice is the most beneficial to: Cardiovascular and Circulatory Disorders, Anxiety, Stress, Tension, Antioxidant, Cleansing, Detoxification, Antispasmodic, Digestive Upsets and Spasms, Anti-Tumor, High Cholesterol, Memory Loss, Male impotency, Menstrual disorders, Mood Boosting, Taste Enhance. Discover Epicure Garden exquisite EXIR Saffron line of Products for healthier living, and fine gourmet cooking. Europe has passion and indulges itself with line quality of our products for decades.

BMV Quantum Subliminal CD End Depression (Ultrasonic Peak Mental Health Series)

BMV Quantum Subliminal CD End Depression (Ultrasonic Peak Mental Health Series)

Program your childs subconscious mind to alleviate symptoms related to depression. Increase your overall peace of mind, energy levels, happiness and your excitement for life. Exclusive state-of-the-art subliminal and brainwave entrainment technologies that you can use to program your subconscious mind for positive lasting results, created by a Certified Hypnotherapist and NLP Practitioner (Neuro-Linguistic Programming). Silent affirmations, hypnotic suggestions and thousands of powerful subliminal messages program your subconscious mind for positive results. The first 3 tracks have an ocean background. The Silent Ultrasonic Track 4 is completely silent with no sound at all! BMVs exclusive Quantum Subliminal Matrix Technology sets a new standard for the subliminal industry! BMV has merged...

  The art of prescribing: antidepressant-induced insomnia: treatment options.: An article from: Perspectives in Psychiatric Care
by Deborah Antai-Otong (Author)

This digital document is an article from Perspectives in Psychiatric Care, published by Nursecom, Inc. on January 1, 2004. The length of the article is 2591 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: The art of prescribing: antidepressant-induced insomnia: treatment options.
Author: Deborah Antai-Otong
Publication: Perspectives in Psychiatric Care (Refereed)
Date: January 1, 2004
Publisher: Nursecom, Inc.
Volume: 40 Issue: 1 Page: 29(5)

Distributed by Thomson...

Rhythms - A Timed Approach to Patient Care (To Increase Compliance in Clinically Depressed Patients)

Rhythms - A Timed Approach to Patient Care (To Increase Compliance in Clinically Depressed Patients)

A video in support of the Rhythms Compliance Program. Pfizer's Rhythms program for depression was singled out for increasing community and employer awareness of depression, providing education and follow-up for patients and offering important tools for health care providers. Rhythms is a 28 week compliance program, based on The Agency for Health Care Policy and Research (AHCPR) Clinical Practice Guideline, and phase-matched to the patients' stage of antidepressant treatment. The Rhythms Compliance Program is a patient assistance program and is intended to support and reinforce instructions to depressed patients. This video is recommended for viewing soon after treatment initiation, although the video is suited for patients at any stage who want to learn more about depression. The Rhythms...

  Symptom amelioration the goal in fibromyalgia treatment. (Analgesics, Antidepressants can Help).: An article from: Internal Medicine News
by Robert Finn (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2003. The length of the article is 497 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Symptom amelioration the goal in fibromyalgia treatment. (Analgesics, Antidepressants can Help).
Author: Robert Finn
Publication: Internal Medicine News (Magazine/Journal)
Date: March 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 5 Page: 17(1)

Distributed by Thomson...

  Use of Antidepressants in the Treatment of Child and Adolescent Depression: Are They Effective?: An article from: Pediatric Nursing
by Zendi Moldenhauer (Author), Bernadette Mazurek Melnyk (Author)

This digital document is an article from Pediatric Nursing, published by Jannetti Publications, Inc. on November 1, 1999. The length of the article is 3678 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Use of Antidepressants in the Treatment of Child and Adolescent Depression: Are They Effective?
Author: Zendi Moldenhauer
Publication: Pediatric Nursing (Refereed)
Date: November 1, 1999
Publisher: Jannetti Publications, Inc.
Volume: 25 Issue: 6 Page: 643

Distributed by Thomson...

  The New Yorker, Feb. 17, 1992 "Memory During Antidepressant Treatment"
by Karen Rose (Author), James (cover art) Stevenson (Illustrator)



© 2009 BrightSurf.com